In the RP2D cohort, there were 29 patients with cHL refractory to PD-(L)1 blockade, defined as the patients who had disease progression within 3 months after the last dose of PD-(L)1 blockade. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.